Mantle Cell Lymphoma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
View More
Dr Goy shares highlights of recent innovations in the treatment of patients with MCL.
View More
Preetesh Jain, MBBS, MD, DM, PhD, discusses a study that explores the definition, current challenges, and management of high-risk MCL.
View More
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period…
View More
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
View More
David A. Bond, MD, talks about a study from ASCO 2020 regarding practice patterns and predictors of survival in older patients with MCL in the rituximab era.
View More
David A. Bond, MD, provides an overview of the background and findings of the ZUMA-2 clinical trial.
View More
Michael Dickinson, MBBS (Hons), D.Med Sci, FRACP, FRCPA, discusses the results of a phase 1 dose escalation study of glofitamab in relapsed/refractory NHL.
View More
Javier Munoz, MD, MS, FACP, discusses the significance of the ZUMA-2 trial and how KTE-X19 could potentially fit in the treatment pathway for patients with MCL.
View More
Stay in the know.
OncNet Newsletter